Welcome to the international HTA database

Showing [25027 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V]
2025	Agency for Healthcare Research and Quality (AHRQ)	Assisted home dialysis in the United States: new interest in an old idea
2025	NIHR Health Services and Delivery Research programme	The implementation of safety management systems in healthcare: a systematic review and international comparison
2025	NIHR Health and Social Care Delivery Program	After the disruptive innovation: how remote and digital services were embedded, blended and abandoned in UK general practice – longitudinal study
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2025	Agency for Healthcare Research and Quality (AHRQ)	Association between outcomes and dental services in people at risk of post-transplant complications: a rapid response review
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Irradiation of the skin with intense pulsed light and radiofrequency for stage I and II hidradenitis suppurativa (Hurley Score)]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Overview of applications of extended reality technologies in health and social services]
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Patient-specific 3D-printed models in surgical planning: mapping review of clinical indications and scoping review of organizational and legal aspects]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Linvoseltamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2025	Agency for Healthcare Research and Quality (AHRQ)	Association between outcomes and dental services in people receiving treatment for human immunodeficiency virus: a rapid response review
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Proton pump inhibitors: deprescription and lifestyle changes]
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[The safety, efficacy, effectiveness, efficiency, and organizational impact of mHealth tools for guided telerehabilitation that enable telemonitoring in neck pain, low back pain, and painful shoulder]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V]
2025	Agency for Healthcare Research and Quality (AHRQ)	Association between outcomes and dental services in people receiving treatments that cause medication-related osteonecrosis of the jaw: a rapid response review
2025	Health Technology Wales (HTW)	Long length peripheral intravenous catheters for patients with difficult intravenous access
2025	NIHR Health Services and Delivery Research programme	Witness to harm-holding to account. Improving patient, family and colleague experiences of fitness to practise proceedings: a mixed-methods study
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ixekizumab (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V]
2025	Agency for Healthcare Research and Quality (AHRQ)	Association between outcomes and dental services in people with substance use disorder: a rapid response review
2025	Gesundheit Osterreich GmbH (GOeG)	[Efficacy and safety of antibody therapies in early-stage Alzheimer's disease]
2025	NIHR Health Technology Assessment programme	Diagnostic strategies for suspected acute aortic syndrome: systematic review, meta-analysis, decision-analytic modelling and value of information analysis
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sepiapterin (phenylketonuria) – Addendum to Project G25-23]
2025	Agency for Healthcare Research and Quality (AHRQ)	Association of digestible carbohydrate intake with cardiovascular disease, type 2 diabetes, obesity, and body composition
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Bispecific and tumor-infiltrating T cell therapies: considerations for deployment in Quebec]
2025	Institute of Health Economics (IHE)	PET/CT capacity for cancer diagnosis and follow-up: rapid review
2025	NIHR Health Services and Delivery Research programme	Post-pandemic planning for maternity care for local, regional, and national maternity systems across the four nations: a mixed-methods study
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Securing scientific research without PubMed and ClinicalTrials.gov]
2025	Agency for Healthcare Research and Quality (AHRQ)	Blood-based tests for multiple cancer screening: a systematic review
2025	NIHR Health Services and Delivery Research programme	Team-based motivational engagement intervention in young people with first-episode psychosis: the EYE-2 cluster RCT with economic and process evaluation
2025	NIHR Health Technology Assessment programme	A community-based rehabilitation package following hip fracture: FEMuR III a multi-centre RCT, economic and process evaluation
2025	Agency for Healthcare Research and Quality (AHRQ)	Breastfeeding and health outcomes for infants and children
2025	NIHR Health Technology Assessment programme	Management of diarrhoea in patients with stable ulcerative colitis with low FODMAP diet, amitriptyline, ondansetron or loperamide: the MODULATE RCT
2025	NIHR Health Technology Assessment programme	Cost-effectiveness of endoscopic treatments for obesity: a clinical evidence map and systematic review to inform a model-based cost-effectiveness analysis
2025	Agency for Healthcare Research and Quality (AHRQ)	Comparative effectiveness of medical therapies for locally advanced gastric adenocarcinoma
2025	NIHR Health Technology Assessment programme	The acceptability of blood spot screening and genome sequencing in newborn screening: a systematic review examining evidence and frameworks
2025	NIHR Health Services and Delivery Research programme	Integration of specialised services for eating disorders and functional symptom disorders in children and young people: discrete choice experiments and qualitative study
2025	Agency for Healthcare Research and Quality (AHRQ)	Digestible carbohydrate intake and maternal-infant outcomes: a systematic review
2025	Penn Medicine Center for Evidence-based Practice (CEP)	Dedicated staff for placement of indwelling urinary catheters
2025	Health Technology Wales (HTW)	Digital rehabilitation and self-management interventions for chronic kidney disease
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[RT-qPCR monitoring of NPM1 variants for measurable residual disease in acute myeloid leukemia]
2025	Agency for Healthcare Research and Quality (AHRQ)	Examining the impact of implementing high-reliability organization principles on patient safety outcomes
2025	Health Sciences Institute in Aragon (IACS)	Programme for the use of real world data in health technology assessment: using real-world data for health technology assessment
2025	Health Technology Wales (HTW)	Thermal ablation of liver metastases in people with colorectal cancer
2025	Agency for Healthcare Research and Quality (AHRQ)	Fiber intake and laxation in people with normal bowel function
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[ADHD and driving performance]
2025	National Institute for Health and Care Excellence (NICE)	Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal). NICE technology appraisal guidance 1078
2025	Health Technology Wales (HTW)	MAF-gene tests to guide adjuvant bisphosphonate treatment in breast cancer
2025	HTA Region Stockholm	[Therapeutic benefits and adverse effects of extended idebenone treatment in Leber hereditary optic neuropathy (LHON)]
2025	Agency for Healthcare Research and Quality (AHRQ)	Implementing recommended mental health and substance use screening and counseling interventions in primary care settings for children and adolescents
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Assesment of artificial intelligence´s diagnostic yield and security in cardiac monitoring using insertable cardiac monitors]
2025	Agency for Care Effectiveness (ACE)	Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults
2025	National Institute for Health and Care Excellence (NICE)	Sparsentan for treating primary IgA nephropathy. NICE technology appraisal guidance 1074
2025	NIHR Health Services and Delivery Research programme	‘Come and work here!’ Qualitative research exploring community-led initiatives to improve healthcare recruitment and retention in remote and rural areas
2025	Austrian Institute for Health Technology Assessment (AIHTA)	Transition from child and adolescent to adult mental health services: analysis of international models and recommendations for action for Austria
2025	Agency for Healthcare Research and Quality (AHRQ)	Interventions to improve care of bereaved persons
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Alternative methods to coercive measures]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Prediction models in dental care - basis for the National Board of Health and Welfare’s mission to develop a national model for risk assessment in dental care]
2025	Agency for Care Effectiveness (ACE)	Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
2025	National Institute for Health and Care Excellence (NICE)	Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies. NICE technology appraisal guidance 1073
2025	NIHR Health Technology Assessment programme	Perioperative oxygen therapy in patients undergoing surgical procedures: an overview of systematic reviews and meta-analyses
2025	Austrian Institute for Health Technology Assessment (AIHTA)	Enfortumab vedotin in combination with pembrolizumab in urothelial cancer
2025	Agency for Healthcare Research and Quality (AHRQ)	Interventions to prevent nonventilator hospital-acquired pneumonia
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Effectiveness and complications of preimplantation genetic testing for aneuploidies (PGT-A) in in vitro fertilisation (IVF)]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Appropriate use of cardiac monitoring in the emergency department]
2025	National Institute for Health and Care Excellence (NICE)	Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1071
2025	NIHR Health Services and Delivery Research programme	Identifying acceptable and effective methods of assessing perinatal anxiety: the MAP study
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Artificial intelligence in medical imaging: fields of application and considerations for its deployment in Quebec]
2025	Agency for Healthcare Research and Quality (AHRQ)	Living systematic review on cannabis and other plant-based treatments for chronic pain
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Adaptive deep brain stimulation in Parkinson's disease]
2025	Agency for Care Effectiveness (ACE)	Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer
2025	National Institute for Health and Care Excellence (NICE)	Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1072
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of Luspatercept (Reblozyl)]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Onasemnogene abeparvovec (spinal muscular atrophy): Review of the study protocol (Version 5.01) and statistical analysis plan (Version 5.01) – Sixth addendum to Project A20-61]
2025	Agency for Healthcare Research and Quality (AHRQ)	Making healthcare safer IV: programs for responding to harms experienced by patients during clinical care
2025	Agency for Care Effectiveness (ACE)	Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer
2025	National Institute for Health and Care Excellence (NICE)	Spesolimab for treating generalised pustular psoriasis flares. NICE technology appraisal guidance 1070
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the clinical safety and efficacy of transcutaneous and percutaneous posterior tibial nerve stimulation in patients with overactive bladder syndrome or neurogenic lower urinary tract dysfunction refractory to conventional pharmacological treatment]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Acalabrutinib (mantle cell lymphoma; monotherapy) – Addendum to Project A25-90]
2025	Agency for Care Effectiveness (ACE)	Edison Histotripsy System for non-invasive destruction of liver tumours
2025	Agency for Healthcare Research and Quality (AHRQ)	Making healthcare safer IV: use of structured handoff protocols for intrahospital within-unit transitions
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Phonocardiography to rule out coronary heart disease]
2025	Agency for Care Effectiveness (ACE)	Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
2025	National Institute for Health and Care Excellence (NICE)	Linzagolix for treating symptoms of endometriosis. NICE technology appraisal guidance 1067
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Tumor biomarkers related to the management of advanced cutaneous melanoma]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Acalabrutinib (mantle cell lymphoma; combination with bendamustine and rituximab) – Second addendum to Project A25-89]
2025	Agency for Care Effectiveness (ACE)	LumiSystem for intraoperative tumour margin assessment following breast-conserving surgery
2025	Agency for Healthcare Research and Quality (AHRQ)	Management of suicidal thoughts and behaviors in youth: a systematic review
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for the update of the DMP “type 2 diabetes”]
2025	Agency for Care Effectiveness (ACE)	Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025	National Institute for Health and Care Excellence (NICE)	Efgartigimod for treating antibody-positive generalised myasthenia gravis. NICE technology appraisal guidance 1069
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with venetoclax) – Addendum to Project A25-85]
2025	Agency for Care Effectiveness (ACE)	Portable Neuromodulation Stimulator (PoNS) for treating gait deficit due to multiple sclerosis
2025	Agency for Healthcare Research and Quality (AHRQ)	Measure criteria for the Agency for Healthcare Research and Quality's National Healthcare Quality and Disparities Report
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	Monitoring study protocol: left ventricular assist devices destination therapy
2025	NIHR Health Technology Assessment programme	Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT
2025	Agency for Care Effectiveness (ACE)	Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma
2025	National Institute for Health and Care Excellence (NICE)	Somapacitan for treating growth hormone deficiency in people 3 to 17 years. NICE technology appraisal guidance 1066
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Overview of service use to address the medical needs of seniors receiving home care]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with venetoclax and obinutuzumab) – Addendum to Project A25-91]
2025	Agency for Care Effectiveness (ACE)	Biomarker-based brain trauma assessment tests to aid in the evaluation of mild traumatic brain injury in adults